Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice
- PMID: 17909013
- DOI: 10.1158/0008-5472.CAN-07-2887
Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice
Abstract
In this report, we have investigated the relationship between androgen levels and prostate tumorigenesis in Nkx3.1; Pten mutant mice, a genetically engineered mouse model of human prostate cancer. By experimentally manipulating serum levels of testosterone in these mice for an extended period (i.e., 7 months), we have found that prolonged exposure of Nkx3.1; Pten mutant mice to androgen levels that are 10-fold lower than normal (the "Low-T" group) resulted in a marked acceleration of prostate tumorigenesis compared with those exposed to androgen levels within the reference range (the "Normal-T" group). We found that prostate tumors from the Low-T mutant mice share a similar gene expression profile as androgen-independent prostate tumors from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as Vav3 and Runx1. We propose that exposure to reduced androgens may promote prostate tumorigenesis by selecting for molecular events that promote more aggressive, hormone-refractory tumors.
Similar articles
-
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer.Genomics. 1997 Jul 1;43(1):69-77. doi: 10.1006/geno.1997.4715. Genomics. 1997. PMID: 9226374
-
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.Cancer Res. 2005 Dec 15;65(24):11565-71. doi: 10.1158/0008-5472.CAN-05-3441. Cancer Res. 2005. PMID: 16357166
-
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.Cancer Res. 2006 Mar 1;66(5):2815-25. doi: 10.1158/0008-5472.CAN-05-4000. Cancer Res. 2006. PMID: 16510604
-
Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1.Ann N Y Acad Sci. 2005 Nov;1059:33-40. doi: 10.1196/annals.1339.018. Ann N Y Acad Sci. 2005. PMID: 16382041 Review.
-
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. BJU Int. 2009. PMID: 19558559 Review.
Cited by
-
The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.Cancer Res. 2013 Jul 1;73(13):3997-4008. doi: 10.1158/0008-5472.CAN-12-3929. Epub 2013 May 6. Cancer Res. 2013. PMID: 23650284 Free PMC article.
-
Survival following primary androgen deprivation therapy among men with localized prostate cancer.JAMA. 2008 Jul 9;300(2):173-81. doi: 10.1001/jama.300.2.173. JAMA. 2008. PMID: 18612114 Free PMC article.
-
Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.J Mol Endocrinol. 2013 Jun 29;51(1):143-53. doi: 10.1530/JME-13-0060. Print 2013. J Mol Endocrinol. 2013. PMID: 23709748 Free PMC article.
-
Emerging Biomarker-Guided Therapies in Prostate Cancer.Curr Oncol. 2022 Jul 18;29(7):5054-5076. doi: 10.3390/curroncol29070400. Curr Oncol. 2022. PMID: 35877260 Free PMC article. Review.
-
Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.Mol Cancer Res. 2017 Nov;15(11):1469-1480. doi: 10.1158/1541-7786.MCR-17-0280. Epub 2017 Aug 15. Mol Cancer Res. 2017. PMID: 28811363 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials